Tag:
patents
Latest Headlines
Latest Headlines
Brennan's ouster at AstraZeneca sets stage for big changes in R&D
The ongoing restructuring underway at AstraZeneca claimed one more employee today: The chief architect.
Is M&A getting too pricey for smart drugmakers?
Is pharma's current penchant for M&A the right way to tackle patent-cliff setbacks?
Experts jab over drug patent reform and the best approach to innovation
One of the most persistent arguments in the biopharma business these days is focused squarely on the length of patent protection a new treatment has when it goes on the market. The industry has
Ireland's exports set to fall off the patent cliff
The patent cliff is like a yurt. It has many sides. To Big Pharma, it's been a looming threat for years. To generics makers, it's a multibillion-dollar boon. To India, with its generics-heavy pharma
FTC chief laments 63% boost in generic settlements
You can't accuse Federal Trade Commission Chairman Jon Leibowitz of being a quitter. The agency chief is on his generic settlements soapbox again, saying that the number of deals delaying copycat
Pharma's Q1 to benefit from higher prices
Most major U.S. drugmakers' first-quarter results are likely to benefit from higher prices as the industry continues efforts to bolster product pipelines ahead of the expiration of patent protection
Alzheimer's mice at center of academic vs. property rights
Nature News tells a tale involving transgenic mice, the future of Alzheimer's research and property rights. In the end, it sounds as though the only winners will be the lawyers. At issue is the
Gene-patent courtroom drama plays out in Washington
The Salt Lake Tribune caught some of the courtroom drama going on at the U.S. Circuit Court of Appeals on Monday, as three judges heard arguments for and against the ability of a private company to
Former MS programmer assails software patents
"Anyone who supports software patents should hold up a good one and explain how it is actually unique and yet an idea that only one company should own," writes After the Software Wars author and
U.S. reverses stance on genes and patents
In a continuing courtroom drama , the federal government filed a brief on Friday saying that genes should not be patentable because they are a part of nature. The New York Times says the position, a
